Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy - PubMed (original) (raw)
Clinical Trial
Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy
B Michael Ghadimi et al. J Clin Oncol. 2005.
Abstract
Purpose: There is a wide spectrum of tumor responsiveness of rectal adenocarcinomas to preoperative chemoradiotherapy ranging from complete response to complete resistance. This study aimed to investigate whether parallel gene expression profiling of the primary tumor can contribute to stratification of patients into groups of responders or nonresponders.
Patients and methods: Pretherapeutic biopsies from 30 locally advanced rectal carcinomas were analyzed for gene expression signatures using microarrays. All patients were participants of a phase III clinical trial (CAO/ARO/AIO-94, German Rectal Cancer Trial) and were randomized to receive a preoperative combined-modality therapy including fluorouracil and radiation. Class comparison was used to identify a set of genes that were differentially expressed between responders and nonresponders as measured by T level downsizing and histopathologic tumor regression grading.
Results: In an initial set of 23 patients, responders and nonresponders showed significantly different expression levels for 54 genes (P < .001). The ability to predict response to therapy using gene expression profiles was rigorously evaluated using leave-one-out cross-validation. Tumor behavior was correctly predicted in 83% of patients (P = .02). Sensitivity (correct prediction of response) was 78%, and specificity (correct prediction of nonresponse) was 86%, with a positive and negative predictive value of 78% and 86%, respectively.
Conclusion: Our results suggest that pretherapeutic gene expression profiling may assist in response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. The implementation of gene expression profiles for treatment stratification and clinical management of cancer patients requires validation in large, independent studies, which are now warranted.
Conflict of interest statement
Authors’ Disclosures of Potential Conflicts of Interest
The authors indicated no potential conflicts of interest.
Figures
Fig 1
Pictorial presentation of specimen accrual, clinical diagnosis, and experimental design. cUICC refers to pretherapeutic clinical staging of tumors. ypUICC refers to histopathologic assessment of the resected specimens after completion of preoperative therapy. UICC, International Union Against Cancer; FU, fluorouracil.
Fig 2
Flow of statistical analyses for cDNA and oligonucleotide data. Gray ovals represent data, rectangles represent statistical procedures, and round-edged boxes indicate results. The figure shows the three main statistical analyses performed. Class prediction (red) and class comparison (blue) for cDNA data and cross-platform normalization for the classification of oligonucleotide data (green) is shown.
Fig 3
Hierarchical cluster analysis of 23 patients based on the 54 most significantly changed genes (P < .001) when using T level downsizing. Red indicates increased expression, and green indicates decreased expression. Gene symbols and fold change between the groups are listed to the right. Values less than 1 reflect downregulation in the class of responders, whereas values more than 1 reflect upregulation. P, patient.
Similar articles
- Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group. Rödel C, et al. Lancet Oncol. 2015 Aug;16(8):979-89. doi: 10.1016/S1470-2045(15)00159-X. Epub 2015 Jul 15. Lancet Oncol. 2015. PMID: 26189067 Clinical Trial. - Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T, Langer C, Ghadimi BM, Kulle B, Aust DE, Baretton GB, Schwabe W, Häusler P, Becker H, Jakob C. Liersch T, et al. J Clin Oncol. 2006 Sep 1;24(25):4062-8. doi: 10.1200/JCO.2005.04.2739. J Clin Oncol. 2006. PMID: 16943523 - Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer.
Rimkus C, Friederichs J, Boulesteix AL, Theisen J, Mages J, Becker K, Nekarda H, Rosenberg R, Janssen KP, Siewert JR. Rimkus C, et al. Clin Gastroenterol Hepatol. 2008 Jan;6(1):53-61. doi: 10.1016/j.cgh.2007.10.022. Clin Gastroenterol Hepatol. 2008. PMID: 18166477 - Preoperative chemoradiotherapy in locally advanced rectal cancer: correlation of a gene expression-based response signature with recurrence.
Liersch T, Grade M, Gaedcke J, Varma S, Difilippantonio MJ, Langer C, Hess CF, Becker H, Ried T, Ghadimi BM. Liersch T, et al. Cancer Genet Cytogenet. 2009 Apr 15;190(2):57-65. doi: 10.1016/j.cancergencyto.2008.11.011. Cancer Genet Cytogenet. 2009. PMID: 19380020 Free PMC article. - Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer.
Akiyoshi T, Kobunai T, Watanabe T. Akiyoshi T, et al. Surg Today. 2012 Aug;42(8):713-9. doi: 10.1007/s00595-012-0223-8. Epub 2012 Jun 16. Surg Today. 2012. PMID: 22706722 Review.
Cited by
- Treatment response prediction of neoadjuvant chemotherapy for rectal cancer by deep learning of colonoscopy images.
Kato S, Miyoshi N, Fujino S, Minami S, Nagae A, Hayashi R, Sekido Y, Hata T, Hamabe A, Ogino T, Tei M, Kagawa Y, Takahashi H, Uemura M, Yamamoto H, Doki Y, Eguchi H. Kato S, et al. Oncol Lett. 2023 Sep 20;26(5):474. doi: 10.3892/ol.2023.14062. eCollection 2023 Nov. Oncol Lett. 2023. PMID: 37809043 Free PMC article. - Introducing novel key genes and transcription factors associated with rectal cancer response to chemoradiation through co-expression network analysis.
Afshar S, Leili T, Amini P, Dinu I. Afshar S, et al. Heliyon. 2023 Aug 2;9(8):e18869. doi: 10.1016/j.heliyon.2023.e18869. eCollection 2023 Aug. Heliyon. 2023. PMID: 37636389 Free PMC article. - Nonoperative management of gastrointestinal malignancies in era of neoadjuvant treatment.
Chen N, A Ajani J, Wu A. Chen N, et al. Chin J Cancer Res. 2023 Feb 28;35(1):44-57. doi: 10.21147/j.issn.1000-9604.2023.01.05. Chin J Cancer Res. 2023. PMID: 36910854 Free PMC article. - Transcriptomic Analyses of Pretreatment Tumor Biopsy Samples, Response to Neoadjuvant Chemoradiotherapy, and Survival in Patients With Advanced Rectal Cancer.
Akiyoshi T, Wang Z, Kaneyasu T, Gotoh O, Tanaka N, Amino S, Yamamoto N, Kawachi H, Mukai T, Hiyoshi Y, Nagasaki T, Yamaguchi T, Konishi T, Fukunaga Y, Noda T, Mori S. Akiyoshi T, et al. JAMA Netw Open. 2023 Jan 3;6(1):e2252140. doi: 10.1001/jamanetworkopen.2022.52140. JAMA Netw Open. 2023. PMID: 36662520 Free PMC article.
References
- Nelson H, Sargent DJ. Refining multimodal therapy for rectal cancer. N Engl J Med. 2001;345:690–692. - PubMed
- Minsky BD. Adjuvant therapy for rectal cancer: The transatlantic view. Colorectal Dis. 2003;5:416–422. - PubMed
- Sauer R. Adjuvant and neoadjuvant radiotherapy and concurrent radiochemotherapy for rectal cancer. Pathol Oncol Res. 2002;8:7–17. - PubMed
- Pasche B, Mulcahy M, Benson AB., 3rd Molecular markers in prognosis of colorectal cancer and prediction of response to treatment. Best Pract Res Clin Gastroenterol. 2002;16:331–345. - PubMed
- Adlard JW, Richman SD, Seymour MT, et al. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol. 2002;3:75–82. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources